# Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

> **NCT01358578** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1306 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Placebo
- **DRUG:** secukinumab (AIN457)
- **DRUG:** etanercept

## Key facts

- **NCT ID:** NCT01358578
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 1306 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358578, "Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01358578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*